Foghorn Therapeutics (FHTX) Total Current Liabilities (2019 - 2026)

Foghorn Therapeutics' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $64.4 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 9.68% year-over-year to $64.4 million in Q1 2026; TTM through Mar 2026 was $64.4 million, a 9.68% decrease from a year earlier, with the FY2025 full-year figure at $59.7 million, down 10.82% from the prior year.
• Total Current Liabilities improved to $64.4 million in Q1 2026 per FHTX's latest filing, from $59.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $85.1 million in Q3 2025 and bottomed at $48.0 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $56.6 million (2023), against an average of $59.7 million.
• Across the five-year window, Total Current Liabilities jumped 195.39% in 2022 and retreated 10.82% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $55.2 million in 2022, then grew by 5.85% to $58.4 million in 2023, then climbed by 14.64% to $67.0 million in 2024, then retreated by 10.82% to $59.7 million in 2025, then advanced by 7.81% to $64.4 million in 2026.
• Per Business Quant, the three latest FHTX Total Current Liabilities figures stand at $64.4 million (Q1 2026), $59.7 million (Q4 2025), and $85.1 million (Q3 2025).